WO2011083150A2 - Obesity small molecules - Google Patents

Obesity small molecules Download PDF

Info

Publication number
WO2011083150A2
WO2011083150A2 PCT/EP2011/050186 EP2011050186W WO2011083150A2 WO 2011083150 A2 WO2011083150 A2 WO 2011083150A2 EP 2011050186 W EP2011050186 W EP 2011050186W WO 2011083150 A2 WO2011083150 A2 WO 2011083150A2
Authority
WO
WIPO (PCT)
Prior art keywords
cyp3a4
compound
abcb1
jun
mice
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2011/050186
Other languages
English (en)
French (fr)
Other versions
WO2011083150A3 (en
Inventor
Josef Penninger
Andrew Pospisilik
Shane Mcmanus
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AKRON MOLECULES GmbH
Original Assignee
AKRON MOLECULES GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AKRON MOLECULES GmbH filed Critical AKRON MOLECULES GmbH
Priority to CA2786777A priority Critical patent/CA2786777A1/en
Priority to EP11700051A priority patent/EP2521594A2/en
Priority to JP2012547515A priority patent/JP2013516442A/ja
Priority to US13/520,961 priority patent/US20130030007A1/en
Publication of WO2011083150A2 publication Critical patent/WO2011083150A2/en
Anticipated expiration legal-status Critical
Publication of WO2011083150A3 publication Critical patent/WO2011083150A3/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • a recommended oral starting dose of dasatinib in chronic phase CML is 100 mg once daily.
  • the recommended starting dose for accelerated, myeloid, or lymphoid blast phase CML or Phila ⁇ delphia chromosome-positive ALL is 70 mg twice daily.
  • Doses of up to 140 mg once daily have been used in patients with chronic phase CML, and up to 100 mg twice daily in those with advanced phase CML, or with ALL. It may also be administered 15 to 240 mg per day (60kg adult human dose), preferably orally.
  • Pazopanib is a multi-targeted receptor tyrosine kinase in ⁇ hibitor. It has been approved for treatment of renal cell carci ⁇ noma. Pazopanib may also be active in ovarian cancer and soft tissue sarcoma and in the treatment of non-small cell lung car ⁇ cinoma .
  • Eskazine EGR1 MAPT 1958,4137 CG7847, CG31057 0
  • HGF HGF, ABCB1, JUN, PDP 2, 5243, 3725, 5170, 275,CG13744,CG387
  • HSP90AB1 Monorden HSP90AB1, HSPA4, FG 3326, 3308, 2247, 33 CGI 242, CG6603, CG4 B F2, DNAJBl, HSP90AA 37, 3320 608,CG10578,CG124

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicinal Preparation (AREA)
PCT/EP2011/050186 2010-01-07 2011-01-07 Obesity small molecules Ceased WO2011083150A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CA2786777A CA2786777A1 (en) 2010-01-07 2011-01-07 Obesity small molecules
EP11700051A EP2521594A2 (en) 2010-01-07 2011-01-07 Obesity small molecules
JP2012547515A JP2013516442A (ja) 2010-01-07 2011-01-07 肥満症に用いる小分子
US13/520,961 US20130030007A1 (en) 2010-01-07 2011-01-07 Obesity Small Molecules

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10150270.6 2010-01-07
EP10150270 2010-01-07

Publications (2)

Publication Number Publication Date
WO2011083150A2 true WO2011083150A2 (en) 2011-07-14
WO2011083150A3 WO2011083150A3 (en) 2012-07-26

Family

ID=43533338

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2011/050186 Ceased WO2011083150A2 (en) 2010-01-07 2011-01-07 Obesity small molecules

Country Status (5)

Country Link
US (1) US20130030007A1 (enExample)
EP (2) EP2521594A2 (enExample)
JP (1) JP2013516442A (enExample)
CA (1) CA2786777A1 (enExample)
WO (1) WO2011083150A2 (enExample)

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104812898A (zh) * 2012-05-25 2015-07-29 博格有限责任公司 通过调节热休克蛋白质(HSP)90-β治疗代谢综合征的方法
CN105287552A (zh) * 2015-10-27 2016-02-03 中国科学院广州生物医药与健康研究院 阿西替尼的新应用
US20170216286A1 (en) * 2014-01-28 2017-08-03 Mayo Foundation For Medical Education And Research Killing senescent cells and treating senescence-associated conditions using a src inhibitor and a flavonoid
EP3200795A4 (en) * 2014-10-02 2018-06-20 Yeda Research and Development Co., Ltd. Use of agents for treating fat-related disorders
US10023864B2 (en) 2014-06-06 2018-07-17 Berg Llc Methods of treating a metabolic syndrome by modulating heat shock protein (HSP) 90-beta
US10213426B2 (en) 2014-01-28 2019-02-26 Unity Biotechnology, Inc. Method of optimizing conditions for selectively removing a plurality of senescent cells from a tissue or a mixed cell population
CN109464443A (zh) * 2018-10-10 2019-03-15 中国科学院广州生物医药与健康研究院 Linifanib的新应用
WO2020188496A1 (en) * 2019-03-18 2020-09-24 Moshe Rogosnitzky Stable liquid naltrexone compositions
WO2021101814A1 (en) * 2019-11-19 2021-05-27 The George Washington University Intranasal leptin prevents opioid-induced respiratory depression in obesity
CN119842713A (zh) * 2025-02-17 2025-04-18 江苏省家禽科学研究所 一种靶向抑制鸡PLCB2基因表达的siRNA及其应用
WO2025081219A1 (en) * 2023-10-19 2025-04-24 St Vincent's Institute Of Medical Research Methods of treating conditions with sik3 inhibitors
US12285427B2 (en) 2014-01-28 2025-04-29 Unity Biotechnology, Inc. Treatment of a senescence-associated ocular disease or disorder using a Bcl-xL selective inhibitor

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2675275B1 (en) * 2011-02-14 2017-12-20 The Regents Of The University Of Michigan Compositions and methods for the treatment of obesity and related disorders
ES2727898T3 (es) 2013-05-02 2019-10-21 Univ Michigan Regents Amlexanox deuterado con estabilidad metabólica mejorada
EP4578865A3 (en) 2014-08-12 2025-07-30 Monash University Lymph directing prodrugs
US20190316204A1 (en) * 2015-07-24 2019-10-17 Korea University Research And Business Foundation Biomarker for determining aging, determining obesity, and diagnosing cancer and diagnosing kit using same
CN108137482B (zh) 2015-09-08 2024-03-15 莫纳什大学 定向淋巴的前药
US10214536B2 (en) 2016-01-29 2019-02-26 The Regents Of The University Of Michigan Amlexanox analogs
WO2017197303A1 (en) * 2016-05-13 2017-11-16 University Of North Carolina At Greensboro Methods and compositions for the inhibition of quorum sensing in bacterial infections
MX392555B (es) * 2016-09-07 2025-03-24 Univ Temple Composiciones y métodos para el tratamiento de resistencia a la insulina.
WO2018128485A1 (ko) * 2017-01-05 2018-07-12 한국생명공학연구원 항-코티닌 키메릭 항원 수용체를 발현하는 자연살해 세포
EP4306524A3 (en) 2017-08-29 2024-09-11 PureTech LYT, Inc. Lymphatic system-directing lipid prodrugs
US11883497B2 (en) 2017-08-29 2024-01-30 Puretech Lyt, Inc. Lymphatic system-directing lipid prodrugs
JP7249397B2 (ja) * 2017-12-27 2023-03-30 日本化薬株式会社 ダサチニブを有効成分とする医薬組成物
US20220339168A1 (en) * 2019-09-19 2022-10-27 Monash University Methods and compounds for treatment of metabolic disease
KR102376806B1 (ko) * 2020-03-05 2022-03-21 주식회사 메타이뮨텍 오에노테인 b 유사체를 유효성분으로 포함하는 체중 감량용 조성물
TW202206062A (zh) 2020-04-24 2022-02-16 美國坦普大學 高等教育聯邦系統 治療非酒精性脂肪肝炎的方法
JP2023159469A (ja) * 2020-08-24 2023-11-01 国立大学法人 東京大学 肥満症を予防又は治療するための医薬組成物
CN115624980B (zh) * 2022-12-26 2023-03-10 四川大学 一种金属硒基生物催化材料及其制备方法和用途
CN116549435B (zh) * 2023-04-28 2024-04-09 中山大学附属第三医院 一种内质网应激抑制剂及其应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000041698A1 (en) 1999-01-13 2000-07-20 Bayer Corporation φ-CARBOXY ARYL SUBSTITUTED DIPHENYL UREAS AS p38 KINASE INHIBITORS
WO2000042012A1 (en) 1999-01-13 2000-07-20 Bayer Corporation φ-CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS
WO2000051628A2 (en) 1999-03-03 2000-09-08 Biogen, Inc. Methods of modulating lipid metabolism and storage

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LU86099A1 (fr) * 1985-09-30 1987-04-02 Pharlyse Formes galeniques a liberation prolongee du verapamil,leur fabrication et medicaments les contenant
FR2625678B1 (fr) * 1988-01-13 1991-06-07 Delalande Sa Agents anorexigenes a base de n-(quinuclidin-3-yl)-benzamides ou thiobenzamides
FR2681864B1 (fr) * 1991-09-27 1995-03-31 Adir Nouveaux derives bicycliques azotes, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
WO2002090504A2 (en) * 2001-05-03 2002-11-14 Curagen Corporation Novel antibodies that bind to antigenic polypeptides, nucleic acids encoding the antigens, and methods of use
EP1492525A2 (en) * 2001-08-16 2005-01-05 Probiodrug AG Use of inhibitors of proline endopeptidase to modulate inositol (1,4,5) triphosphate concentration dependent on intracellular signal cascades
KR20030083348A (ko) * 2002-04-22 2003-10-30 주식회사 엠디바이오알파 지방세포 분화 저해 활성을 가지는 프로토베르베린알칼로이드 화합물인 베르베린을 유효성분으로 함유하는비만예방 및 치료
CN1481796A (zh) * 2003-06-13 2004-03-17 吴开敏 治疗肥胖症的药物
US20050090554A1 (en) * 2003-09-12 2005-04-28 John Devane Treatment of gastroparesis and nonulcer dyspepsia with GABAB agonists
WO2005115446A2 (en) * 2004-05-21 2005-12-08 Yale University Detection and use of prolylcarboxypeptidase
US8703769B2 (en) * 2005-07-15 2014-04-22 The University Of North Carolina At Chapel Hill Use of EGFR inhibitors to prevent or treat obesity

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000041698A1 (en) 1999-01-13 2000-07-20 Bayer Corporation φ-CARBOXY ARYL SUBSTITUTED DIPHENYL UREAS AS p38 KINASE INHIBITORS
WO2000042012A1 (en) 1999-01-13 2000-07-20 Bayer Corporation φ-CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS
WO2000051628A2 (en) 1999-03-03 2000-09-08 Biogen, Inc. Methods of modulating lipid metabolism and storage

Non-Patent Citations (67)

* Cited by examiner, † Cited by third party
Title
ALTAREJOS ET AL., NATURE MEDICINE, vol. 14, 2008, pages 1112 - 1117
ASHRAFI ET AL., NATURE, vol. 421, 2003, pages 268 - 272
BAKER ET AL., CELL METABOLISM, vol. 6, 2007, pages 257 - 266
BROWN ET AL., THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 277, 2002, pages 32899 - 32904
BUHMAN ET AL., J NUTR, vol. 134, 2004, pages 2979 - 2984
CHOI ET AL., CLIN CANCER RES., vol. 14, no. 16, 15 August 2008 (2008-08-15), pages 5081 - 9
CIARDIELLO ET AL., CLIN CANCER RES., vol. 9, no. 4, April 2003 (2003-04-01), pages 1546 - 56
CYPESS ET AL., N ENGL J MED, vol. 360, 2009, pages 1509 - 1517
DAMIANO ET AL., CLIN CANCER RES., vol. 11, no. 15, 1 August 2005 (2005-08-01), pages 5639 - 44
DIETZL ET AL., NATURE, vol. 448, 2007, pages 151 - 156
DREVS ET AL., ANGIOGENESIS, vol. 7, no. 4, 2004, pages 347 - 54
ENCINOSA ET AL.: "Use and costs of bariatric surgery and prescription weight-loss medications.", HEALTH AFF (MILLWOOD), vol. 24, 2005, pages 1039 - 1046
FAN ET AL., CELL, vol. 81, 1995, pages 457 - 465
FARMER, S.R., CELL METABOLISM, vol. 4, 2006, pages 263 - 273
FARMER, S.R., NATURE, vol. 458, 2009, pages 839 - 840
FAROOQI ET AL., OBES REV, vol. 8, no. 1, 2007, pages 37 - 40
FONTAINE ET AL.: "Years of life lost due to obesity", JAMA, vol. 289, 2003, pages 187 - 193
GESTA ET AL., CELL, vol. 131, 2007, pages 242 - 256
GIANNARELLI ET AL., CIRCULATION, vol. 119, no. 12, 31 March 2009 (2009-03-31), pages 1625 - 33
GRONKE ET AL., CELL METABOLISM, vol. 1, 2005, pages 323 - 330
GRONKE ET AL., PLOS BIOL, vol. 5, 2007, pages 137
GUSTAFSON ET AL., J PHARMACOL EXP THER., vol. 318, no. 2, August 2006 (2006-08-01), pages 872 - 80
GUTIERREZ ET AL., NATURE, vol. 445, 2007, pages 275 - 280
HADER ET AL., EMBO REP, vol. 4, 2003, pages 511 - 516
HEBROK ET AL.: "Regulation of pancreas development by hedgehog signaling", DEVELOPMENT (CAMBRIDGE, ENGLAND), vol. 127, 2000, pages 4905 - 4913
HEINE ET AL., THE JOURNAL OF CLINICAL INVESTIGATION, vol. 119, 2009, pages 267 - 277
HENSRUD ET AL., MAYO CLIN PROC., vol. 81, no. 10, October 2006 (2006-10-01), pages 5 - 10
JIANG ET AL., CELL, vol. 80, 1995, pages 563 - 572
JIANG ET AL., DEV CELL, vol. 15, 2008, pages 801 - 812
KOO ET AL., NATURE, vol. 437, 2005, pages 1109 - 1111
LEE ET AL.: "BMS-354825: a potent dual SRC/ABL kinase inhibitor possessing curative efficacy against imatinib sensitive and resistant human CML models in vivo", AACR 95TH ANNUAL MEETING, 2004
LEFTEROVA ET AL., TRENDS ENDOCRINOL METAB, vol. 20, 2009, pages 107 - 114
LEOPOLD ET AL., NATURE, vol. 450, 2007, pages 186 - 188
LI ET AL., INT J BIOL SCI, vol. 4, 2008, pages 29 - 36
LUO ET AL., CLIN CANCER RES., vol. 12, no. 23, 1 December 2006 (2006-12-01), pages 7180 - 6
MAKINO ET AL., DEVELOPMENTAL BIOLOGY, vol. 239, 2001, pages 95 - 106
MARTIN ET AL., J NEUROCHEM, vol. 98, 2006, pages 279 - 288
MATSUZAKA ET AL., NATURE MEDICINE, vol. 13, 2007, pages 1193 - 1202
MELCHER ET AL., THE JOURNAL OF ENDOCRINOLOGY, vol. 192, 2007, pages 467 - 472
MIN ET AL., SCIENCE (NEW YORK, vol. 284, 1999, pages 1985 - 1988
MORAIN ET AL., BR J CLIN PHARMACOL., vol. 50, no. 4, October 2000 (2000-10-01), pages 350 - 9
NYBAKKEN ET AL., NATURE GENETICS, vol. 37, 2005, pages 1323 - 1332
OLDHAM ET AL., TRENDS CELL BIOL, vol. 13, 2003, pages 79 - 85
ROSEN ET AL., NATURE REVIEWS, vol. 7, 2006, pages 885 - 896
ROSIK CH, OBES SURG., vol. 15, 2005, pages 677 - 683
ROSS ET AL., MOLECULAR AND CELLULAR BIOLOGY, vol. 24, 2004, pages 3505 - 3513
SARWER ET AL., OBES SURG., vol. 14, 2004, pages 1148 - 1156
SCHLEGEL ET AL., PLOS GENET, vol. 3, 2007, pages 199
SEALE ET AL., GENES & DEVELOPMENT, vol. 23, 2009, pages 788 - 797
SPEAKMAN ET AL., LAB ANIM, vol. 42, 2008, pages 413 - 432
SUH ET AL., CELL METABOLISM, 2006
SUH ET AL., CELL METABOLISM, vol. 3, 2006, pages 25 - 34
SUZAWA ET AL., NATURE CELL BIOLOGY, vol. 5, 2003, pages 224 - 230
TAGUCHI ET AL., CANCER SCI., vol. 95, no. 12, December 2004 (2004-12-01), pages 984 - 9
THOMAS ET AL., DIABETES, vol. 49, 2000, pages 2039 - 2047
TSENG ET AL., NATURE, vol. 454, 2008, pages 1000 - 1004
VAN MARKEN LICHTENBELT ET AL., N ENGL J MED, vol. 360, 2009, pages 1500 - 1508
VIRTANEN ET AL., N ENGL J MED, vol. 360, 2009, pages 1518 - 1525
WANG ET AL., PROC NATL ACAD SCI U S A., vol. 107, no. 20, 2010, pages 9323 - 8
WEDGE ET AL., CANCER RES., vol. 62, no. 16, 15 August 2002 (2002-08-15), pages 4645 - 55
WU ET AL., J AM CHEM SOC, vol. 124, 2002, pages 14520 - 14521
YAN ET AL., GENES & DEVELOPMENT, vol. 19, 2005, pages 1662 - 1667
YU ET AL., THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 280, 2005, pages 13600 - 13605
ZEHENTNER ET AL., DNA CELL BIOL, vol. 19, 2000, pages 275 - 281
ZHANG ET AL., NATURE, vol. 372, 1994, pages 425 - 432
ZHANG ET AL., THE BIOCHEMICAL JOURNAL, vol. 306, 1995, pages 205 - 210
ZINGARETTI ET AL., FASEB J, vol. 23, 2009, pages 3113 - 3120

Cited By (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9533002B2 (en) 2012-05-25 2017-01-03 Berg Llc Methods of treating a metabolic syndrome by modulating heat shock protein (HSP) 90-β
CN104812898A (zh) * 2012-05-25 2015-07-29 博格有限责任公司 通过调节热休克蛋白质(HSP)90-β治疗代谢综合征的方法
US10213426B2 (en) 2014-01-28 2019-02-26 Unity Biotechnology, Inc. Method of optimizing conditions for selectively removing a plurality of senescent cells from a tissue or a mixed cell population
US20170216286A1 (en) * 2014-01-28 2017-08-03 Mayo Foundation For Medical Education And Research Killing senescent cells and treating senescence-associated conditions using a src inhibitor and a flavonoid
US11980616B2 (en) 2014-01-28 2024-05-14 Mayo Foundation For Medical Education And Research Treating liver disease by selectively eliminating senescent cells
US12285427B2 (en) 2014-01-28 2025-04-29 Unity Biotechnology, Inc. Treatment of a senescence-associated ocular disease or disorder using a Bcl-xL selective inhibitor
US11351167B2 (en) 2014-01-28 2022-06-07 Buck Institute For Research On Aging Treating cognitive decline and other neurodegenerative conditions by selectively removing senescent cells from neurological tissue
US11963957B2 (en) 2014-01-28 2024-04-23 Mayo Foundation For Medical Education And Research Treating cardiovascular disease by selectively eliminating senescent cells
US10328073B2 (en) 2014-01-28 2019-06-25 Unity Biotechnology, Inc. Use of sulfonamide inhibitors of BCL-2 and BCL-xL to treat ophthalmic disease by selectively removing senescent cells
US10413542B2 (en) 2014-01-28 2019-09-17 Buck Institute For Research On Aging Methods and compositions for killing senescent cells and for treating senescence-associated diseases and disorders using an inhibitor of Akt kinase
US10478433B2 (en) 2014-01-28 2019-11-19 Unity Biotechnology, Inc. Unit dose of an aryl sulfonamide that is effective for treating eye disease and averting potential vision loss
US10478432B2 (en) 2014-01-28 2019-11-19 Unity Biotechnology, Inc. Compositions of matter for treatment of ophthalmic conditions by selectively removing senescent cells from the eye
US10517866B2 (en) 2014-01-28 2019-12-31 Unity Biotechnology, Inc. Removing senescent cells from a mixed cell population or tissue using a phosphoinositide 3-kinase (PI3K) inhibitor
US11517572B2 (en) 2014-01-28 2022-12-06 Mayo Foundation For Medical Education And Research Killing senescent cells and treating senescence-associated conditions using a SRC inhibitor and a flavonoid
US10023864B2 (en) 2014-06-06 2018-07-17 Berg Llc Methods of treating a metabolic syndrome by modulating heat shock protein (HSP) 90-beta
EP3200795A4 (en) * 2014-10-02 2018-06-20 Yeda Research and Development Co., Ltd. Use of agents for treating fat-related disorders
CN105287552A (zh) * 2015-10-27 2016-02-03 中国科学院广州生物医药与健康研究院 阿西替尼的新应用
CN109464443B (zh) * 2018-10-10 2021-08-17 中国科学院广州生物医药与健康研究院 Linifanib的新应用
CN109464443A (zh) * 2018-10-10 2019-03-15 中国科学院广州生物医药与健康研究院 Linifanib的新应用
WO2020188496A1 (en) * 2019-03-18 2020-09-24 Moshe Rogosnitzky Stable liquid naltrexone compositions
WO2021101814A1 (en) * 2019-11-19 2021-05-27 The George Washington University Intranasal leptin prevents opioid-induced respiratory depression in obesity
WO2025081219A1 (en) * 2023-10-19 2025-04-24 St Vincent's Institute Of Medical Research Methods of treating conditions with sik3 inhibitors
CN119842713A (zh) * 2025-02-17 2025-04-18 江苏省家禽科学研究所 一种靶向抑制鸡PLCB2基因表达的siRNA及其应用

Also Published As

Publication number Publication date
JP2013516442A (ja) 2013-05-13
EP2521594A2 (en) 2012-11-14
WO2011083150A3 (en) 2012-07-26
US20130030007A1 (en) 2013-01-31
EP2633884A1 (en) 2013-09-04
CA2786777A1 (en) 2011-07-14

Similar Documents

Publication Publication Date Title
EP2633884A1 (en) Obesity small molecules
ES2800311T3 (es) Nuevos enfoques terapéuticos para tratar la enfermedad de Alzheimer
AU2014372166B2 (en) Pharmaceutical combinations
US20160257957A1 (en) Methods and compositions for treatment of angelman syndrome and autism spectrum disorders
TWI835179B (zh) 胰腺炎治療
EP4615506A1 (en) Use of gsk-3 activatior to modulate proteasome activity to prevent ageing associated conditions and diseases
KR101471238B1 (ko) 약물동력학을 개선하는 방법
US20170114060A1 (en) Novel effective antiviral compounds and methods using same
RU2607944C2 (ru) Синергические композиции ингибиторов pi3k и мек
JP2019206565A (ja) 黒色腫の治療のための組合せ医薬
ES2750662T3 (es) Orvepitant para el tratamiento del prurito crónico
HK1200809A1 (en) Cinnamic acid hydroxyamides as inhibitors of histone deacetylase 8
IL295753A (en) Compositions and therapeutic uses of cannabidiol
KR20240108406A (ko) 2'-데옥시시티딘 유사체를 포함하는 조성물 및 겸상 적혈구 질환, 지중해빈혈, 및 암의 치료를 위한 그의 용도
JP2012526772A (ja) ホスホイノシチド３−キナーゼ阻害剤および抗糖尿病性化合物の組合せ剤
JP2024523126A (ja) Ｎｒｈ、ｎａｒｈ、及びそれらの還元誘導体を用いた免疫関連障害、腎障害、肝障害、溶血性障害、及び酸化的ストレス関連障害の処置
JP2017502056A (ja) 肝障害の治療方法
WO2013029006A1 (en) Dengue virus and yellow fever virus therapies
Qin et al. Small molecule-driven LKB1 deacetylation is responsible for the inhibition of hepatic lipid response in NAFLD
CN114599374A (zh) 用于增强抗癌化合物e7766的治疗依从性的系统
EP1802297B1 (en) Compositions and methods for treatment of disease caused by yersinia spp infection
US12404304B1 (en) Telomerase reverse transcriptase (TERT) expression enhancing compounds and methods for using the same
CA3034460A1 (en) Hair follicle stem cell activation and hair growth
JP2017061445A (ja) ３−［（３−｛［４−（４−モルホリニルメチル）−１ｈ−ピロール−２−イル］メチレン｝−２−オキソ−２，３−ジヒドロ−１ｈ−インドール−５−イル）メチル］−１，３−チアゾリジン−２，４−ジオンとｅｇｆｒチロシンキナーゼ阻害剤との新しい併用
WO2024023696A1 (en) Dosing regimen for a nlrp3 inhibitor

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11700051

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2012547515

Country of ref document: JP

Ref document number: 13520961

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2786777

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2011700051

Country of ref document: EP